Effect of Statin Use During Hospitalization on Short-term Stroke Recurrence in Acute Ischemic Stroke with Chronic Kidney Disease in Chinese Population

doi:10.3969/j.issn.1673-5765.2018.06.003

Abstract

Abstract:

Objective We investigated the effect of statin use during hospitalization in reducing short-term stroke recurrence of patients with acute ischemic stroke and chronic kidney diseases (CKD). Methods Data of first-ever ischemic stroke patients without a history of pre-stroke statin use was derived from the China National Stroke Registry (CNSR). Patients were stratified according to estimated glomerular filtration rate (eGFR): normal renal function [eGFR≥90 ml/(min·1.73 m2)], mild CKD [60 ml/(min·1.73 m2)≤eGFR<90 ml/(min·1.73 m2)] and moderate CKD [eGFR<60 ml/(min·1.73 m2)]. Multi-factors logistic regression analysis was used to evaluate the association between statin use during hospitalization and stroke recurrence with different renal functions at 3-month follow-up. Results Among 5951 patients included, 2595 (43.6%) patients were on statin use during hospitalization after stroke. Compared with non-statin group, statin use during hospitalization was associated with decreased stroke recurrence in patients with mild CKD [odds ratios (OR) 0.69, 95% confidence interval (CI) 0.50-0.95, P =0.02] and moderate CKD (OR 0.48, 95%CI 0.28-0.83, P =0.009) at 3-month follow-up, respectively. Whereas in patients with normal renal function, no significant benefit from statin therapy was detected (OR 0.80, 95%CI 0.60-1.06, P =0.12). Conclusion Statin use during hospitalization was associated with decreased stroke recurrence in ischemic stroke patients with mild and moderate CKD at 3-month follow-up, but not in patients with normal renal function in Chinese population. Further studies are needed to confirm this finding.

Key words: Chronic kidney disease; Acute ischemic stroke; Statin therapy; Stroke recurrence

摘要：

目的分析住院期间使用他汀类药物降低伴有慢性肾病（chronic kidney disease，CKD）的急性缺血性卒中患者短期复发的效果。

方法选取中国国家卒中登记研究（China National Stroke Registry，CNSR）中首次发病，且发病前未服用他汀类药物治疗的缺血性卒中患者作为研究对象。根据肾小球滤过率（estimated glomerular filtration rate，eGFR）将患者分成三组，肾功能正常组[eGFR≥90 ml/（min·1.73 m2）]、轻度CKD组[60 ml/ （mi n·1.73 m2）≤eGFR＜90 ml/（mi n·1.73 m2）]和中度CKD组[eGFR＜60 ml/（min·1.73 m2）]。采用多因素 Logistic回归分析，分析住院期间他汀类药物治疗与不同肾脏功能缺血性卒中患者3个月卒中复发的相关性。

结果在5951例患者中，2595例（43.6%）患者卒中后住院期间使用他汀类药物，与未使用他汀类药物治疗组相比，住院期间使用他汀类药物可以降低伴有CKD的缺血性卒中患者的3个月卒中复发风险，包括轻度CKD组[比值比（odds ratios，OR）0.69，95%可信区间（confidence interval，CI）0.50～0.95， P =0.02]和中度CKD组（OR 0.48，95%CI 0.28～0.83，P =0.009）。然而在肾功能正常组，他汀类药物治疗无明显疗效（OR 0.80，95%CI 0.60～1.06，P =0.12）。

结论在中国人群中，住院期间使用他汀类药物可降低伴有轻度CKD和中度CKD的缺血性卒中患者3个月卒中复发风险，但不能降低正常肾脏功能缺血性卒中患者卒中复发风险，该结论应在更大样本人群中进一步验证。

关键词: 慢性肾脏病; 急性缺血性卒中; 他汀类药物治疗; 卒中复发

LYU Wei, JIANG Yong, ZHANG Xin-Miao, JING Jing, MENG Xia, ZHOU Mai-Geng. Effect of Statin Use During Hospitalization on Short-term Stroke Recurrence in Acute Ischemic Stroke with Chronic Kidney Disease in Chinese Population[J]. Chinese Journal of Stroke, 2018, 13(06): 542-549.

吕微, 姜勇, 张心邈, 荆京, 孟霞, 周脉耕. 住院期间他汀类药物治疗对伴有慢性肾脏病的急性缺血性卒中患者短期卒中复发的影响[J]. 中国卒中杂志, 2018, 13(06): 542-549.

References

[1] LEE M，SAVER J L，CHANG K H，et al. Low

glomerular filtration rate and risk of stroke：metaanalysis[

J/OL]. BMJ，2010，341：4249. https：//doi.

org/10.1136/bmj.c4249.

[2] KIM S J，BANG O Y. Antiplatelet therapy for

preventing stroke in patients with chronic kidney

disease[J/OL]. Contrib Nephrol，2013，179：119-129.

https：//doi.org/10.1159/000346730.

[3] YAHALOM G，SCHWARTZ R，

SCHWAMMENTHAL Y，et al. Chronic kidney

disease and clinical outcome in patients with acute

stroke[J]. Stroke，2009，40（4）：1296-1303.

[4] MOSTOFSKY E，WELLENIUS G A，NOHERIA

A，et al. Renal function predicts survival in patients

with acute ischemic stroke[J]. Cerebrovasc Dis，2009，

28（1）：88-94.

[5] KERNAN W N，OVBIAGELE B，BLACK H R，et

al. Guidelines for the prevention of stroke in patients

with stroke and transient ischemic attack：a guideline

for healthcare professionals from the American Heart

Association/American Stroke Association[J]. Stroke，

2014，45（7）：2160-2236.

[6] MESCHIA J F，BUSHNELL C，BODEN-ALBALA

B，et al. Guidelines for the primary prevention of stroke：a statement for healthcare professionals from

the American Heart Association/American Stroke

Association[J]. Stroke，2014，45（12）：3754-3832.

[7] HONG K S，LEE J S. Statins in acute ischemic

stroke：a systematic review[J]. J Stroke，2015，17（3）：

282-301.

[8] NÍ CHRÓINÍN D，ASPLUND K，ÅSBERG S，et

al. Statin therapy and outcome after ischemic stroke：

systematic review and meta-analysis of observational

studies and randomized trials[J]. Stroke，2013，44

（2）：448-456.

[9] SZUMMER K，LUNDMAN P，JACOBSON S

H，et al. Association between statin treatment and

outcome in relation to renal function in survivors of

myocardial infarction[J]. Kidney Int，2011，79（9）：

997-1004.

[10] TONELLI M，MOYÉ L，SACKS F M，et

al. Pravastatin for secondary prevention of

cardiovascular events in persons with mild chronic

renal insufficiency[J]. Ann Intern Med，2003，138

（2）：98-104.

[11] KEOUGH-RYAN T M，KIBERD B A，DIPCHAND

C S，et al. Outcomes of acute coronary syndrome

in a large Canadian cohort：impact of chronic renal

insufficiency，cardiac interventions，and anemia[J].

Am J Kidney Dis，2005，46（5）：845-855.

[12] HOU W，LV J，PERKOVIC V，et al. Effect of statin

therapy on cardiovascular and renal outcomes in

patients with chronic kidney disease：a systematic

review and meta-analysis[J]. Eur Heart J，2013，34

（24）：1807-1817.

[13] Cholesterol Treatment Trialists（' CTT）Collaboration，

HERRINGTON W G，EMBERSON J，et al. Impact

of renal function on the effects of LDL cholesterol

lowering with statin-based regimens：a meta-analysis

of individual participant data from 28 randomised

trials[J]. Lancet Diabetes Endocrinol，2016，4（10）：

829-839.

[14] TONELLI M，ISLES C，CURHAN G C，et al.

Effect of pravastatin on cardiovascular events in

people with chronic kidney disease[J]. Circulation，

2004，110（12）：1557-1563.

[15] SHEPHERD J，KASTELEIN J J，BITTNER V，et al.

Intensive lipid lowering with atorvastatin in patients

with coronary heart disease and chronic kidney

disease：the TNT（Treating to New Targets）study[J].

J Am Coll Cardiol，2008，51（15）：1448-1454.

[16] AMARENCO P，CALLAHAN A 3RD，CAMPESE

V M，et al. Effect of high-dose atorvastatin on renal

function in subjects with stroke or transient ischemic

attack in the SPARCL trial[J]. Stroke，2014，45（10）：2974-2982.

[17] WANG Y，CUI L，JI X，et al. The China

National Stroke Registry for patients with acute

cerebrovascular events：design，rationale，and

baseline patient characteristics[J]. Int J Stroke，2011，

6（4）：355-361.

[18] WHO Task Force on Stroke and Other

Cerebrovascular Disorders. Stroke--1989.

Recommendations on stroke prevention，diagnosis，

and therapy. Report of the WHO Task Force on

Stroke and other Cerebrovascular Disorders[J].

Stroke，1989，20（10）：1407-1431.

[19] SONG B，WANG Y，ZHAO X，et al. Association

between statin use and short-term outcome based

on severity of ischemic stroke：a cohort study[J/

OL]. PLoS One，2014，9（1）：e84389. https：//doi.

org/10.1371/journal.pone.0084389.

[20] PAN Y，SONG T，CHEN R，et al. Socioeconomic

deprivation and mortality in people after ischemic

stroke：the China National Stroke Registry[J]. Int J

Stroke，2016，11（5）：557-564.

[21] ADAMS H P JR，BENDIXEN B H，KAPPELLE L

J，et al. Classification of subtype of acute ischemic

stroke. Definitions for use in a multicenter clinical

trial. TOAST. Trial of Org 10172 in Acute Stroke

Treatment[J]. Stroke，1993，24（1）：35-41.

[22] WANG Y，XU J，ZHAO X，et al. Association of

hypertension with stroke recurrence depends on

ischemic stroke subtype[J]. Stroke，2013，44（5）：

1232-1237.

[23] TEO B W，XU H，WANG D，et al. GFR estimating

equations in a multiethnic Asian population[J]. Am J

Kidney Dis，2011，58（1）：56-63.

[24] ZHOU Y，PAN Y，WU Y，et al. Effect of estimated

glomerular filtration rate decline on the efficacy and

safety of clopidogrel with aspirin in minor stroke

or transient ischemic attack：CHANCE Substudy

（Clopidogrel in High-Risk Patients With Acute

Nondisabling Cerebrovascular Events）[J]. Stroke，

2016，47（11）：2791-2796.

[25] LUO Y，WANG X，WANG Y，et al. Association of

glomerular filtration rate with outcomes of acute

stroke in type 2 diabetic patients：results from the

China National Stroke Registry[J]. Diabetes Care，

2014，37（1）：173-179.

[26] LUO Y，WANG X，MATSUSHITA K，et al.

Associations between estimated glomerular

filtration rate and stroke outcomes in diabetic versus

nondiabetic patients[J]. Stroke，2014，45（10）：2887-

2893.

[27] LEVEY A S，CORESH J，BALK E，et al. National Kidney Foundation practice guidelines for chronic

kidney disease：evaluation，classification，and

stratification[J]. Ann Intern Med，2003，139（2）：

137-147.

[28] BEST P J，STEINHUBL S R，BERGER P B，et al.

The efficacy and safety of short- and long-term dual

antiplatelet therapy in patients with mild or moderate

chronic kidney disease：results from the Clopidogrel

for the Reduction of Events During Observation

（CREDO）trial[J]. Am Heart J，2008，155（4）：687-

693.

[29] CAPPELLARI M，DELUCA C，TINAZZI M，et

al. Does statin in the acute phase of ischemic stroke

improve outcome after intravenous thrombolysis? A

retrospective study[J]. J Neurol Sci，2011，308（1-2）：

128-134.

[30] FLINT A C，KAMEL H，NAVI B B，et al. Statin

use during ischemic stroke hospitalization is strongly

associated with improved poststroke survival[J].

Stroke，2012，43（1）：147-154.

[31] NÍ CHRÓINÍN D，CALLALY E L，DUGGAN

J，et al. Association between acute statin therapy，

survival，and improved functional outcome after

ischemic stroke：the North Dublin Population Stroke

Study[J]. Stroke，2011，42（4）：1021-1029.

[32] FLINT A C，KAMEL H，NAVI B B，et al. Inpatient

statin use predicts improved ischemic stroke

discharge disposition[J]. Neurology，2012，78（21）：

1678-1683.

[33] AL-KHALED M，MATTHIS C，EGGERS J. Statin

treatment in patients with acute ischemic stroke[J].

Int J Stroke，2014，9（5）：597-601.

[34] WEEKS D L，GREER C L，WILLSON M N. Statin

medication use and nosocomial infection risk in the

acute phase of stroke[J]. J Stroke Cerebrovasc Dis，

2016，25（10）：2360-2367.

[35] TOYODA K，MINEMATSU K，YASAKA M，et

al. The Japan Statin Treatment Against Recurrent

Stroke（J-STARS）Echo Study：Rationale and Trial

Protocol[J]. J Stroke Cerebrovasc Dis，2017，26（3）：595-599.

[36] SONG B，WANG Y，ZHAO X，et al. Inpatient statin

use is associated with decreased mortality of acute

stroke patients with very low low-density lipoprotein

cholesterol[J]. J Stroke Cerebrovasc Dis，2015，24

（10）：2369-2374.

[37] SHIBUI T，NAKAGOMI A，KUSAMA Y，et al.

Impact of statin therapy on renal function and longterm

prognosis in acute coronary syndrome patients

with chronic kidney disease[J]. Int Heart J，2010，51

（5）：312-318.

[38] LIM S Y，BAE E H，CHOI J S，et al. Effect on

short- and long-term major adverse cardiac events

of statin treatment in patients with acute myocardial

infarction and renal dysfunction[J]. Am J Cardiol，

2012，109（10）：1425-1430.

[39] ATHYROS V G，KATSIKI N，KARAGIANNIS A，

et al. Statins can improve proteinuria and glomerular

filtration rate loss in chronic kidney disease patients，

further reducing cardiovascular risk. Fact or

fiction?[J]. Expert Opin Pharmacother，2015，16（10）：

1449-1461.

[40] STRIPPOLI G F，NAVANEETHAN S D，JOHNSON

D W，et al. Effects of statins in patients with chronic

kidney disease：meta-analysis and meta-regression

of randomised controlled trials[J]. BMJ，2008，336

（7645）：645-651.

[41] HALCOX J P，DEANFIELD J E. Beyond

the laboratory：clinical implications for statin

pleiotropy[J]. Circulation，2004，109（21 Suppl 1）：

42-48.

[42] BARYAN H K，ALLAN S M，VAIL A，et al.

Systematic review and meta-analysis of the efficacy

of statins in experimental stroke[J]. Int J Stroke，

2012，7（2）：150-156.

[43] CACHOFEIRO V，GOICOCHEA M，DE VINUESA

S G，et al. Oxidative stress and inflammation，a link

between chronic kidney disease and cardiovascular

disease[J]. Kidney Int Suppl，2008，74（111）：4-9.